Precision Medicine & Diagnostics
Guardant Health
by Guardant Health, Inc.
Blood-based cancer genomic tests enabling earlier detection, treatment guidance, and recurrence monitoring
Category
Precision Medicine & Diagnostics
Founded
2012
Headquarters
Redwood City, CA, USA
Overview
Guardant Health is a precision oncology company focused on developing and commercializing liquid biopsy tests that use circulating tumor DNA (ctDNA) from blood samples to detect cancer genomic alterations, guide treatment selection, and monitor disease progression. Its commercial portfolio includes Guardant360 CDx (an FDA-approved comprehensive genomic profiling test for advanced solid tumors), Guardant Infinity, and Shield (an FDA-approved blood-based colorectal cancer screening test). Oncologists use Guardant360 as an alternative or complement to tissue biopsy when tissue is insufficient, inaccessible, or when real-time genomic monitoring is required. The test detects actionable alterations in 80+ cancer-related genes with a simple blood draw, enabling treatment decisions in under two weeks. Shield, FDA-approved in 2024, is the first blood test approved for average-risk colorectal cancer screening, addressing the large unmet need of colonoscopy-averse patients. Guardant differentiates through its proprietary digital sequencing technology, which achieves exceptionally high sensitivity (detecting ctDNA at allele fractions below 0.1%) by minimizing sequencing error. The company operates a CLIA-certified, CAP-accredited laboratory in Redwood City and has processed over 500,000 clinical tests. Partnerships with AstraZeneca, Bristol Myers Squibb, and Roche validate its companion diagnostic and real-world evidence capabilities.
Key Features
Regulatory Submission Support
Automated documentation and evidence packages for FDA submission of diagnostic tests.
Genomic Biomarker Discovery
AI-powered analysis of clinical sequencing data identifies actionable biomarkers in hours.
Multi-Modal Patient Profiling
Integration of genomic, clinical, imaging, and real-world data for comprehensive patient profiles.
Clinical Trial Matching
Automated matching of patients to clinical trials based on genomic profiles and eligibility criteria.
Companion Diagnostic Development
AI-driven biomarker discovery and validation for companion diagnostic test development.
Pros & Cons
Pros
- +Real-world evidence platform aggregates de-identified patient data from major healthcare systems
- +Multi-modal data integration combines genomic, clinical, and imaging data for comprehensive patient profiling
- +AI-powered genomic analysis identifies actionable biomarkers from clinical sequencing data in hours
- +Longitudinal patient tracking enables outcomes-based analysis of treatment effectiveness
- +Partnerships with 50%+ of US academic medical centers provide diverse patient population coverage
- +FDA-cleared diagnostic tests validate AI-driven biomarker discoveries for clinical use
- +Companion diagnostic development accelerates clinical trial matching and treatment selection
Cons
- −Reimbursement pathways for AI-driven diagnostics remain uncertain in many healthcare markets
- −Requires high-quality, diverse patient datasets that may not be available for rare diseases
- −Clinical validation and regulatory approval processes are lengthy and resource-intensive
- −Clinical adoption depends on physician trust in AI-generated recommendations
Use Cases
Genomic-Guided Treatment Selection
AI-powered analysis of patient genomic data to identify actionable biomarkers and match patients to optimal therapies.
Clinical Trial Matching
Automated matching of patients to clinical trials based on genomic profile, medical history, and trial eligibility criteria.
Real-World Evidence Generation
Aggregation and analysis of de-identified patient data from healthcare systems to generate real-world evidence.